Allogene Therapeutics, Inc. - ALLO STOCK NEWS

Allogene Therapeutics (Nasdaq: ALLO) announced that the FDA has placed a clinical hold on its AlloCAR T trials following the detection of a chromosomal abnormality in a patient treated with ALLO-501A. The patient showed a partial response but developed progressive pancytopenia and aplastic anemia, leading to an investigation into the abnormality's clinical significance. The company believes data from the ALPHA trials support a favorable profile for ALLO-501A, and it is working closely with the FDA to address any potential clinical implications.

Allogene Therapeutics (Nasdaq: ALLO) announced the addition of Dr. Jae Park, a leading expert in cell therapies, to its Scientific Advisory Board. Dr. Park, associated with Memorial Sloan Kettering Cancer Center, has extensive experience in CAR T therapies and is the principal investigator for multiple clinical trials. This appointment aims to enhance Allogene's research capabilities in developing allogeneic CAR T (AlloCAR T™) therapies for various cancers. The company seeks to leverage Dr. Park's expertise to advance its initiatives in treating blood cancers and solid tumors.

Allogene Therapeutics (Nasdaq: ALLO), a clinical-stage biotechnology company, announced its participation in two virtual investor conferences. The first is the H.C. Wainwright 23rd Annual Global Investment Conference on September 13, 2021, at 4:00 AM PT. The second is the BofA Global Research Global Healthcare Conference on September 16, 2021, at 10:25 AM PT. Webcasts will be available on their website following the events. Allogene specializes in allogeneic CAR T therapies aimed at making cell therapy more accessible to patients worldwide.

Allogene Therapeutics announced that the FDA granted orphan-drug designation (ODD) to its ALLO-715 therapy for multiple myeloma. This follows the previous Regenerative Medicine Advanced Therapy (RMAT) designation received in April 2021. The Phase 1 UNIVERSAL trial showed ALLO-715 can achieve clinical responses without the need for bridging therapy. The company plans to update on the trial by the end of 2021. With ODD, the therapy is entitled to various development incentives, including potential marketing exclusivity.

Allogene Therapeutics (ALLO) provided a significant update on its clinical pipeline and financials for Q2 2021. The company showcased promising data from its CD19 program, revealing a 75% overall response rate and 50% complete response rate in CAR T naïve patients with relapsed/refractory non-Hodgkin lymphoma. Financially, Allogene ended the quarter with $913 million in cash. Despite a net loss of $70.9 million, the company remains focused on pivotal trials for ALLO-501A and the development of new therapies, including ALLO-605, which received FDA Fast Track designation.

Allogene Therapeutics has appointed Elizabeth Barrett and Vicki Sato, Ph.D., to its Board of Directors, enhancing its leadership as it prepares for the industry's first pivotal trial of allogeneic CAR T therapy. Barrett, a veteran in oncology commercialization, previously led UroGen Pharma and Novartis Oncology, managing key CAR T launches. Dr. Sato brings her extensive experience from Vertex Pharmaceuticals and Biogen, focusing on unlocking the potential of cell therapy. Their expertise aims to bolster Allogene's efforts to deliver on-demand, off-the-shelf CAR T therapies.

Allogene Therapeutics (Nasdaq: ALLO) will announce its second quarter 2021 financial results on August 4, 2021, post-market close. The company, which specializes in developing allogeneic CAR T therapies for cancer, plans to host a live audio webcast at 2:00 PM PT/5:00 PM ET to discuss these results. The event aims to provide insights into the company's progress and future plans in the rapidly evolving field of biotechnology. Interested parties can access the webcast via the company's website.

Allogene Therapeutics, a clinical-stage biotechnology company based in South San Francisco, announced its participation in two virtual investor conferences. The events include William Blair's Biotech Focus Conference on July 14, 2021, at 5:55 AM PT and Canaccord Genuity's 41st Annual Growth Conference on August 11, 2021, at 7:00 AM PT. Webcasts will be available on their website under the Investors tab, with replays accessible for 30 days thereafter. Allogene focuses on developing allogeneic CAR T therapies for cancer, aiming for accessible and reliable cell therapy solutions.

Allogene Therapeutics has initiated the Phase 1 IGNITE Dose Escalation Trial for ALLO-605, a next-generation AlloCAR T therapy targeting BCMA for relapsed or refractory multiple myeloma. The FDA granted Fast Track designation to ALLO-605, highlighting its potential to address unmet medical needs. ALLO-605 employs TurboCAR technology, which enhances AlloCAR T cell function, potentially making it effective against solid tumors and hematologic malignancies. Allogene is pursuing an aggressive strategy with multiple candidates to benefit patients suffering from multiple myeloma.